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ﬁnd biomarkers for BrS diagnosis and to investigate possible mecha-
nism of BrS, we conducted this study.
METHODS Twenty-ﬁve control patients, 25 BrS patients without
SCN5A mutations and 20 BrS patients with SCN5A mutations were
included in this study. Blood samples were collected in BD Vacutainer
9NC 0.129M (BD Biosciences). White blood cells were separated using
Lympholyte-H sterile liquid. Total RNA was isolated by using Trizol
(Life Technologies) and Direct-Zol RNA MiniPrep Kit and was
reverse transcribed with QuatntiTect Reverse Transcription Kit (Qia-
gen). Real-time quantitative PCR (Q-PCR) analysis was performed
using 7500-Fast Real-Time PCR Systems with MESP1 speciﬁc primers
and probes and TaqMan Gene Expression Master Mix (Life Tech-
nologies). MESP1 expression level was normalized by GAPDH. Differ-
ences between the groups were examined by one way ANOVA and
t-tests. Results with p <0.05 were considered statistically signiﬁcant
in all analyses.
RESULTS Among 5 cardiac speciﬁc transcription factors tested, MESP1
is one of the two expressed in white blood cells (WBC). WBC levels of
MESP1 were signiﬁcantly lower in BrS patients than that in normal
control group (1.080.8 in control group vs. 0.660.38 in BrS patients
without SCN5A mutation, 0.440.42 in BrS patients with SCN5A
mutation respectively, P ¼0.001 by ANOVA analysis). T-tests revealed
that the difference between control group, BrS group without SCN5A
mutation and BrS group with SCN5A mutation is statistically signiﬁ-
cant (P ¼0.012 and P¼0.000 respectively). Nevertheless, there was no
difference detected between the two BrS groups (P¼0.215). The area
under the Receiver Operating Characteristics analysis (ROC) curve for
prediction of BrS using MESP1 levels is 0.775 (95% CI 0.668, 0.882,
asymptotic Sig.¼0.000). At the optimal cutoff, the corresponding
maximum sensitivity and speciﬁcity were 0.62 (95% CI: 0.47, 0.76)
and 0.88 (0.69, 0.97), respectively.
CONCLUSIONS MESP1 is a major cardiac speciﬁc transcription factor
that expresses in white blood cells. Patients with BrS have reduced
circulating MESP1. Our results suggest that assessment of circulating
MESP1 may be used as a biomarker for BrS diagnosis. Our results also
suggest that decreased expression of MESP1 may be one of patho-
physiological mechanism of BrS.GW26-e5401
The effect of atorvastatin on endogenous H2S formation in red blood cell
Yonghao Lan, Mazhan, Xingshan Zhao
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OBJECTIVES To conﬁrm whether can atorvastatin affect the level of
H2S in plasma through the observation on atherosclerosis model of
rabbits, to assess whether atorvastatin can affect the formation of H2S
from erythrocytes. We would like to know more about the mechanism
of the effect of statins on endogenous H2S formation, for providing
new ideas of variant of H2S-directed pharmacotherapy.
METHODS We chose 36 male Japanese big ear rabbits and divide
into 3 groups randomly, including normal group, high-fat-fed
without medicine group(control group) and high-fat-fed with medi-
cine group(statin group). 12 rabbits in the normal group are given
normal diet. Others 24 rabbits are given high fat diet for 12 weeks.
Rabbits in statin group are given atorvastatin 20mg everyday for 8
weeks (13 to 20 weeks). Determinating the level of H2S and MPST
from erythrocytes and the level of H2S in plasma to examine
mechanism of the effect of statins on endogenous H2S formation.
We measure the level of H2S in plasma by sensitive sulphur elec-
trode assay, measure MPST by western blotting. According to the
principle of MPST enzyme catalytic reaction, we measure the level
of H2S from erythrocytes.
RESULTS The level of H2S released from erythrocytes in high-fat-fed
group was signiﬁcant higher than normal group (p <0.05). There were
little differences in the level of H2S in red blood cell among each group
after 8 weeks (p >0.05). The level of H2S released from erythrocytes
in normal group had no changes before and after observation, but it
reduced remarkably in high-fat-fed without medicine group after
observing 8 weeks (p<0.05), it had little changes in high-fat-fed with
medicine group after taking atorvastatin 8 weeks (P >0.05). MPST
expression in erythrocytes were resemblance among each group
(p >0.05). The level of H2S in plasma in high-fat-fed without medicine
group was signiﬁcant lower than normal group (p <0.05). It was
obviously higher in high-fat-fed with medicine group than in high-
fat-fed without medicine group (p <0.05). The level of H2S in plasma
in high-fat-fed with medicine group was lower than normal group,
but no statistical difference (p >0.05).CONCLUSIONS Atorvastatin increase net H2S production by inhibit-
ing its mitochondrial oxidation and reducing CoQ concentration.
However atorvastatin can not affect the formation of endogenous H2S
released from erythrocytes depended mainly on MPST pathway.
Therefore atorvastatin can not affect endogenous H2S formation in red
blood cell.
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cardio-cerebral events in patients with type 2 diabetes and stable coronary
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OBJECTIVES Glycated albumin (GA) and the endogenous secretory
receptor for advanced glycation endproducts (esRAGE) may modulate
risk related to atherosclerosis. We tested the hypothesis that elevated
GA and reduced esRAGE in serum are associated with adverse clinical
outcomes in patients with type 2 diabetes and stable coronary artery
disease (CAD).
METHODS We determined GA and esRAGE serum levels in 576
consecutive patients with type 2 diabetes and stable CAD undergoing
sirolimus-eluting stent (SES)-PCI. The primary endpoint was the
incidence of major adverse cardio-cerebral events (MACCE) including
cardiac death, non-fatal myocardial infarction, and non-fatal stroke
during a 2-year follow-up. The secondary endpoint was the occur-
rence of clinically driven repeat revascularization during a 2-year
follow-up. The prognostic value of GA and esRAGE was determined
with the Cox-proportional hazards model after adjustment for
covariates.
RESULTS A total 40 patients (6.9%) experienced MACCE, and 108
(18.8%) patients underwent repeat coronary revascularization during
the follow-up. Serum GA levels correlated positively (both p<0.001),
while serum esRAGE levels negatively (both p<0.05), with the pri-
mary and secondary endpoints, respectively. Serum GA (HR¼1.220,
95% CI 1.160-1.283; HR¼1.152, 95% CI 1.113-1.191, respectively; both
p<0.001) and esRAGE (HR¼0.597, 95% CI 0.407-0.874; HR¼0.751, 95%
CI 0.613-0.919, respectively; both p<0.01) levels remained indepen-
dent predictors of the primary and secondary endpoints after
adjustment for possible confounders.
CONCLUSIONS Serum GA and esRAGE are novel predictors of long-
term clinical outcomes in patients with type 2 diabetes and stable
CAD. Increased serum GA and decreased esRAGE are associated with a
poor prognosis in such patients.
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OBJECTIVES Pre-clinical studies have shown that hypoxia pre-
conditioning can enhance stem cell therapeutic potential for
myocardial repair. We sought to investigate the safety and feasibility
of intracoronary administration of hypoxia-preconditioned bone
marrow cells (HP-BMCs) for acute ST segment elevation myocardial
infarction (STEMI).
METHODS We randomized 22 patients with acute STEMI to receive
intracoronary administration of normoxia BMCs (N-BMCs) (n¼11) or
HP-BMCs (n¼11) following successful revascularization. Another
14 patients were recruited as the control (n¼14).
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adverse cardiovascular events at 30 days and 1 year among three
groups. There was signiﬁcant improvement in the change of end-
diastolic volume (LVEDV) in HP-BMC group compared with N-BMC
or control at 12 months (P<0.05). No differences were observed in
the change of left ventricular ejection fraction (LVEF), left ven-
tricular end-systolic volume (LVESV) or wall motion score index
(WMSI) among three groups. Nonetheless LVESV were decreased in
the HP-BMCs group compared with baseline (P<0.05, within
group), but not the N-BMCs or control group. WMSI was improved
in HP-BMCs and N-BMCs group (P<0.05, within group), but not in
control. The ratio of myocardial perfusion defect determined
by SPECT decreased in HP-BMCs and N-BMCs groups (P<0.05,
within group), but no signiﬁcant differences were observed among
three groups.
CONCLUSIONS Our results provide the ﬁrst-in-man evidence that
intracoronary administration of HP-BMCs following acute MI appears
to be safe and feasible. These results provide the basis for future
prospective randomized clinical trials in a larger patient cohort.
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Circulating miR-499 are novel and sensitive biomarker of acute
myocardial infarction
Lizhu Zhang, Xi Chen, Tong Su, Heng Li, Qiang Huang, Dan Wu,
Zhijun Han, Chengjian Yang
Wuxi Second People’s Hospital of Nanjing Medical University
OBJECTIVES The aim of this study was to investigate the value of
plasma microRNA-499 (miR-499) as a novel biomarker for early
diagnosis of acute myocardial infarction (AMI).
METHODS Enrolled in this study were 227 patients with chest pain on
presentation to the departments of emergency and cardiology of Wuxi
Second People’s Hospital between October 2011 and May 2014. Addi-
tional 100 healthy individuals who received physical examination in
the same hospital during the same period were used as control.
Plasma was collected at admission, and the abundance of miR-499
was measured using reverse transcriptase-polymerase chain reaction
(RT-PCR).
RESULTS MiR-499 was signiﬁcantly elevated in 142 patients diag-
nosed with AMI as compared with 85 patients in non-AMI group and
100 subjects in healthy control group. Plasma miR-499 were already
detectable in the plasma as early as 1 h after onset of chest pain in AMI
patients, and continued to increase gradually without any sign of
decreasing tendency within 9 h in AMI patients. miR-499 was highly
positively correlated with the serum creatine kinase-MB (CK-MB) and
cTnI. The area under the curve (AUC) of miR-499 for the diagnosis
of AMI was 0.86, with an optimal cut-off value of 4.79, sensitivity of
80%, and speciﬁcity of 80.28%.
CONCLUSIONS miR-499 was shown to substantially increase the
diagnostic accuracy of CK-MB and cTnI in the diagnosis of AMI, and
therefore it may prove to be a useful marker for early diagnosis
of AMI.
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OBJECTIVES Accumulating evidence suggests that xanthine oxidase
(XO) activation is one of the major sources of reactive oxygen species
(ROS) and may play an important role in the initiation and perpetu-
ation of atrial ﬁbrillation (AF). XO inhibitor allopurinol may exert
beneﬁcial effects on diabetes-related atrial remodeling. We aimed to
investigate the potential beneﬁts of allopurinol on atrial remodeling
and atrial ﬁbrillation (AF) promotion in alloxan-induced diabetic
rabbits.
METHODS 48 alloxan-induced diabetic rabbits were randomly
divided into three groups (16 for each): diabetic group (DM group),
diabetic allopurinol treatment group (DA group, 25mg/day/kg) and
control group (C group). Eight rabbits in each group were respec-
tively used to electrophysiological study, and another eight rabbits
from each group were monitored hemodynamics and recorded SBP,
DBP and LVEDP and then sacriﬁced to histological study and western
blotting analysis. After 8-week treatment, isolated Langendorffperfused rabbit hearts were used to evaluate atrial electrophysio-
logical parameters and vulnerability to AF which examined by burst
and S1S2 pacing. Collagen volume fraction (CVF) was calculated by
Masson staining. Western-blot analysis was applied to assess atrial
protein expression of ERK, P38, p-P38, JNK, TGF-band NF-kB p50 in
left atrial tissue.
RESULTS There were no signiﬁcant difference regarding SBP, DBP,
LVEDP and AERP in the three groups. Intra-atrial conduction time
(IACT) was prolonged and AF inducibility was increased in DM group
(41/240 vs. 3/240, P<0.05) compared with controls, which were
markedly reduced by allopurinol (41/240 vs. 4/240, P <0.05). Allo-
purinol also attenuated atrial structural remodeling, with signiﬁcant
reduction in CVF. Western-blot analysis revealed DM increased pro-
tein expression of ERK, P38, p-P38, JNK, TGF-band NF-kB p50, which
were reduced by allopurinol.
CONCLUSIONS Allopurinol suppresses AF promotion by preventing
atrial electrical and structural remodeling, which may be due to its
anti-inﬂammatory and anti-oxidative characteristics. These results
suggest that XO activation may play an important role in the diabetes-
related atrial remodeling.
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OBJECTIVES The study aims to explore whether the FKBP12.6 is the
causative gene of HCM, further more to provide new sight for HCM in
molecular genetics research, clinical diagnosis and treatment.
METHODS In reference to Chinese experts consensus in 2007, Amer-
ican Cardiology Foundation / America Heart Association (ACCF/AHA)
in 2011 and European Society of Cardiology (ESC) issued guidelines for
the diagnosis and management of hypertrophic cardiomyopathy. The
study was approved by hospital ethics committee and all subjects
were gave a written informed consent, we enrolled in Thirty seven
HCM patients and collected the clinical data and peripheral venous
blood (2-5 mL). Genome DNA was extracted from peripheral venous
blood. All exons and exon- intron junctions of the FKBP12.6 gene were
screened to determine whether there are gene variances via direct
sequencing. Control group: two hundred healthy individuals with
same ethnic background.
RESULTS
1. Thirty seven patients with HCM were enrolled in the study. There are
twenty three men and fourteen women, the mean age of these pa-
tients was 54.2415.84 years. Two patients with deﬁnite family his-
tory of HCM, besides one patient with family history unexplained
sudden death. The echocardiogram or cardiac magnetic reso-
nance revealed that thickness of interventricular septal was
19.343.903 mm, thickness of left ventricular posterior wall was 11.0
(10.00, 13.00) mm and ten patients with left ventricular outﬂow tract
obstruction. ST-T change was the most common manifestation on
ECG, the incidence was up to 72.97%, atrial arrhythmia up to 32.4%,
ventricular arrhythmia up to 29.73%, block and Wolf-Parkinson-
White syndrome up to 5.41%, pathological Q wave up to 10.81%.
2. One patient with two single nucleotide polymorphisms (SNP) was
identiﬁed by gene sequencing, including FKBP12.6- c.4161T >
C(NM_004116.3:c.38-36T >C), T-to-C substitution at nucleotide site
4161, c.11278A>T (NM_054033.2:c.198þ 57A >T), A-to-T substitution
at nucleotide site 11278. The above SNP were located at exon- intron
junctions. The patient was 35-year-old female was diagnosed as
asymmetric hypertrophic obstructive cardiomyopathy, cardiac ar-
rhythmias: atrial Beckoning tachycardia, atrial premature beat. The
main symptom was recurrent syncope in 13 years, without previous
history of hypertension, diabetes, hyperthyroidism history, The
echocardiogram showed that thickness of intervent - ricular septal
was 20mm, thickness of left ventricular posterior wall was 9mm and
SAM sign was positive.
CONCLUSIONS This study is the ﬁrst to explore the molecular
genetic relationship between FKBP12.6 gene and HCM. We ﬁnd that
two SNP located at the intron of FKBP12.6 gene, which is lower
than the frequency of healthy people reported by 1000 Genomes
Project Database. In our conclusion, FKBP12.6 gene may not be the
causative gene of HCM, but it still needs to increase the sample size
to further conﬁrm.
